Literature DB >> 171066

Pathological review of breast lesions analyzed for estrogen receptor protein.

P P Rosen, C J Menendez-Botet, J S Nisselbaum, J A Urban, V Miké, A Fracchia, M K Schwartz.   

Abstract

This report provides a detailed pathological review of 333 specimens analyzed for estrogen receptor protein (ERP) and correlates a series of morphological features with ERP results. Included were 147 primary breast carcinomas, 78 metastases, 27 fibroadenomas, and 81 nonneoplastic tissues, all from women. ERP in cytosols was assayed by incubation with [3H]estradiol in the presence and absence of "cold" estradiol followed by dextran-charcoal treatment. Results were summarized as positive (greater 60% inhibition by nontritiated estradiol, greater than 10 fmoles/mg protein), negative (less than 60% inhibition by nontritiated estradiol, less than 10 fmoles/mg protein), or intermediate borderline combinations. ERP in primary tumors ranged from 0.2 to 358 fmoles/mg protein (54.4% positive, 35.4% negative, 10.2% borderline). New findings are: (a) a high frequency of positive ERP in invasive lobular carcinoma (12 of 13, 92.3%) compared to typical ductal tumors (64 of 117, 54.7%); and (b) low frequency of positive ERP(5 of 21, 23.8%) in tumors with a prominent local lymphocyte reaction. Three ERP-positive noncarcinomatous specimens were fibroadenomas of high epithelial cellularity from patients under 30 years. No statistically significant relationship existed between ERP and any other morphological features that were examined.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 171066

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  Oestrogen receptors in mucinous carcinoma of the breast: an immunohistological study using paraffin wax sections.

Authors:  S Shousha; A T Coady; T Stamp; K R James; J Alaghband-Zadeh
Journal:  J Clin Pathol       Date:  1989-09       Impact factor: 3.411

2.  Histochemical demonstration of endogenous estrogen in breast carcinomas: biochemical and clinical correlation.

Authors:  I Katayama; M Shimizu; M Miura; M Maruyama; M Kobayashi; Y Iino; M Izuo; S Wakatsuki
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

Review 3.  Lobular carcinoma of the breast: an overview.

Authors:  E R Fisher; B Fisher
Journal:  Ann Surg       Date:  1977-04       Impact factor: 12.969

4.  Significance of the Tritiated Thymidine Labeling Index in breast cancers.

Authors:  K Araki; M Kimura; K Sakamoto; R Nishimura; M Akagi
Journal:  Jpn J Surg       Date:  1985-03

5.  Predictors of recurrence in stage I (T1N0M0) breast carcinoma.

Authors:  P P Rosen; P E Saigo; D W Braun; E Weathers; A DePalo
Journal:  Ann Surg       Date:  1981-01       Impact factor: 12.969

Review 6.  Management of in situ and minimally invasive breast carcinoma.

Authors:  E R Frykberg; K I Bland
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

7.  Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors.

Authors:  M Stierer; H Rosen; R Weber; H Hanak; J Spona; H Tüchler
Journal:  Ann Surg       Date:  1993-07       Impact factor: 12.969

8.  Multiple steroid receptors in human breast cancer. III. Relationships between steroid receptors and the state of differentiation and the activity of carcinomas throughout the pathologic features.

Authors:  P M Martin; P H Rolland; J Jacquemier; A M Rolland; M Toga
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

9.  Relationship between the content of estrogen and progesterone receptors and the pathological characteristics in human breast cancer.

Authors:  R Nishimura; A Misumi; M Kimura; T Tokunaga; M Akagi
Journal:  Jpn J Surg       Date:  1982

10.  Expression of the estrogen receptor gene in developing and adult human breast.

Authors:  M Boyd; R H Hildebrandt; S A Bartow
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.